Proteomic Analysis of Sera From Individuals With Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated With Clinical Improvement During Imatinib Mesylate Treatment

Journal of Rheumatology - Canada
doi 10.3899/jrheum.160833
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Journal of Rheumatology

Related search

Observational Study of Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis

Journal of Rheumatology
RheumatologyAllergyImmunology
2009English

Organizing Diffuse Alveolar Damage Associated With Progressive Systemic Sclerosis

Mayo Clinic Proceedings
Medicine
1997English

Serum Levels of Soluble Carbonic Anhydrase IX Are Decreased in Patients With Diffuse Cutaneous Systemic Sclerosis Compared to Those With Limited Cutaneous Systemic Sclerosis

BioScience Trends
BiochemistryHealthMedicineGeneticsMolecular Biology
2014English

An MIF Promoter Polymorphism Is Associated With Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis

Journal of Rheumatology
RheumatologyAllergyImmunology
2017English

Estimating Benefits From Immunesuppressive Treatment in Diffuse Cutaneous Systemic Sclerosis: Data From the Canadian Scleroderma Research Group

Open Journal of Rheumatology and Autoimmune Diseases
2014English

Imatinib Mesylate Associated With Delayed Hematopoietic Recovery After Concomitant Chemotherapy

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2004English

Epstein-Barr Virus-Associated Lymphoproliferative Disease During Imatinib Mesylate Treatment for Chronic Myeloid Leukemia

Haematologica
Hematology
2019English

Systemic Sclerosis With Atypical Cutaneous Involvement: A Case Report

2019English

Diffuse Systemic Sclerosis

2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy